Loyal Valley Capital
VC Fund
Shanghai, China
Loyal Valley Capital is a thematic, research-driven private equity firm.
- Total investments:
- 107
- Last investment:
- Lead investor:
- 45%
- Fund size:
- $465M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Loyal Valley Capital invests in
Stages Loyal Valley Capital invests in
Countries Loyal Valley Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.7M–$279M
- Series B
- $25M–$148M
- Series C
- $29M–$300M
Investment Focus
Industry
- Biotechnology 28 (26%)
- Health Care 20 (19%)
- Pharmaceutical 13 (12%)
- Medical 8 (7%)
- Manufacturing 8 (7%)
Stage
- Series C 20 (19%)
- Series A 19 (18%)
- Series B 19 (18%)
- Private Equity 13 (12%)
- Funding Round 12 (11%)
Country
- China 66 (62%)
- United States 4 (4%)
- Hong Kong 1 (1%)
- The Netherlands 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Jay Gu
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Roy Xie
Managing Director and Head of Healthcare Investments
|
Managing Director and Head of Healthcare Investments | Total investments: 5 | Find email | |
Andy Lin
Founding Partner
|
Founding Partner | Total investments: 3 | Find email | |
Chengbin Li
Partner
|
Partner | Total investments: 0 | Find email | |
Jason Zhao
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
China Immunotech
|
China Immunotech is a small molecule innovative drug R&D company developing immune cell therapy technologies and products. Including CAR-T and TCR-T cell therapy with independent intellectual property rights. It was founded in March 2018 by famous immunologists. | $29.4M / Series C / Jul 06, 2026 | |
DeepSeek
|
DeepSeek is an artificial intelligence software company that focuses on developing open-source large language models (LLMs). The company researches and develops AI models, machine learning, natural language processing (NLP), and other advanced AI applications. DeepSeek offers an AI assistant app powered by its latest DeepSeek-V3 model. The companyhas released DeepSeek-R1, an open-source model that rivals OpenAI's offerings, which can be freely distilled and commercialized under the MIT license. | $7.4B / Series A / Jun 16, 2026 | |
YolTech Therapeutics
|
Yaotang (Shanghai) Biotechnology is a high-tech biotechnology company focusing on developing a new generation of mRNA drugs and gene editing drugs by combining mRNA in vivo delivery technology and gene editing technology. Through the continuous development and optimization of CRISPR, base editing and other new-generation gene editing tools, andinnovative improvements to the next-generation mRNA production platform and lipid nanocarrier assembly process, Yaotang Bio is committed to developing treatments for genetic diseases and cardiovascular disease. | $73.8M / Series C / May 29, 2026 | |
Microtide Biotechnology
|
Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine. | $7.3M / Series A / Apr 29, 2026 | |
Galaxea AI
|
Xinghaitu is an intelligent robot technology company that specializes in the development of humanoid robots with embodied intelligence. | $144.7M / Series B / Feb 11, 2026 | |
PulseCare
|
PulseCare is a medtech company that specializes in innovative medical devices and solutions for cardiac and pan-vascular treatment. | $14M / Series A / Nov 06, 2025 | |
GRIT Biotechnology
|
GRIT Biotechnology develops tumor infiltration lymphocytes immunotherapy for solid tumors. The company was founded in 2019 and is headquartered in Shanghai, China. | $84M / Series C / Oct 14, 2025 | |
Core Medical Technology
|
Core Medical Technology is a technology enterprise mainly engaged in the research, production, development, and sales of implantable left ventricular assist devices, extracorporeal ventricular assist devices, percutaneous interventional ventricular assist devices, and equipment. The company was founded in 2016 and is based in Shenzhen, China. | $100M / Series D / Apr 24, 2025 | |
Sinovent
|
Founded in 2016, Sinovent is a global biopharmaceutical company focused on innovation. Sinovent is centered around global standard excellence through its advanced biotechnology platform, decades of management experience, as well as financial support. Sinovent uniquely combines its expertise in science, management and finance, to develop and promoteadvanced treatment methods to solve worldwide healthcare problems. Currently, the company has 12 products in development, primarily in oncology, auto-immune diseases, and infectious diseases. | $97.3M / Series E / Feb 20, 2024 | |
DP Technology
|
Deep Technology uses a new generation of molecular simulation technology to tackle micro-scale industrial design difficulties. Founded in 2018 and is based in Beijing China. | $99.2M / Aug 18, 2023 | |
| See all 107 investments → | |||
Co-Investors
Qiming Venture Partners
12 deals together
Lilly Asia Ventures
10 deals together
Tencent
9 deals together
IDG Capital
7 deals together
OrbiMed
7 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Loyal Valley Capital invest in?
Loyal Valley Capital invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series C and Series A stage. Most of the 107 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Loyal Valley Capital's check size?
Loyal Valley Capital typically joins rounds of $2.7M–$279M at Series A, $25M–$148M at Series B and $29M–$300M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Loyal Valley Capital participates in.
How do I contact Loyal Valley Capital?
Public channels for Loyal Valley Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Loyal Valley Capital?
The team at Loyal Valley Capital includes Jay Gu (Managing Director), Roy Xie (Managing Director and Head of Healthcare Investments) and Andy Lin (Founding Partner), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
